Matching articles for "Revatio"
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
The Medical Letter on Drugs and Therapeutics • October 31, 2022; (Issue 1662)
A reader asked us to review use of the
phosphodiesterase-5 (PDE5) inhibitor sildenafil for
treatment of Alzheimer's disease...
A reader asked us to review use of the
phosphodiesterase-5 (PDE5) inhibitor sildenafil for
treatment of Alzheimer's disease (AD).
Sublingual Nitroglycerin Powder (GoNitro)
The Medical Letter on Drugs and Therapeutics • December 5, 2016; (Issue 1509)
The FDA has approved a sublingual powder formulation
of nitroglycerin (GoNitro – Espero) for prevention
or acute relief of an attack of angina pectoris. It
is the first powder formulation of nitroglycerin...
The FDA has approved a sublingual powder formulation
of nitroglycerin (GoNitro – Espero) for prevention
or acute relief of an attack of angina pectoris. It
is the first powder formulation of nitroglycerin to
become available in the US. Most patients with
angina use sublingual nitroglycerin tablets (Nitrostat,
and generics). Translingual spray formulations of
nitroglycerin (NitroMist, Nitrolingual Pumpspray, and
generics) are also available.
Selexipag (Uptravi) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • February 15, 2016; (Issue 1488)
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral...
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral prostacyclin analog,
was approved earlier for this indication.
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • January 4, 2016; (Issue 1485)
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this...
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this indication.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • January 19, 2015; (Issue 1460)
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure...
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF) or systolic heart failure. Patients
with a LVEF ≥50% and symptoms of heart failure
are considered to have heart failure with preserved
ejection fraction (HFpEF) or diastolic heart failure;
there is little evidence that drug treatment improves
clinical outcomes in these patients. The treatment of
acute heart failure is not included here.
Riociguat (Adempas) for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • March 3, 2014; (Issue 1437)
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary...
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is not an
option. It is the first drug to be approved for treatment
of CTEPH.
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • February 17, 2014; (Issue 1436)
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist...
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist approved for PAH. It is a derivative
of bosentan (Tracleer), which is also manufactured
by Actelion, and is scheduled to become available generically
in 2015. Riociguat (Adempas), another new drug for
this indication, will be reviewed in a future issue.
Volibris
NitroMist Nitroglycerin Spray for Angina
The Medical Letter on Drugs and Therapeutics • March 21, 2011; (Issue 1360)
The FDA has approved a lingual aerosol formulation of nitroglycerin (NitroMist – Akrimax) for acute relief of an attack or acute prophylaxis of angina pectoris. It is the second nitroglycerin lingual spray to...
The FDA has approved a lingual aerosol formulation of nitroglycerin (NitroMist – Akrimax) for acute relief of an attack or acute prophylaxis of angina pectoris. It is the second nitroglycerin lingual spray to become available in the US; Nitrolingual Pumpspray was approved in 1985. Most patients with angina use sublingual nitroglycerin tablets.
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • November 2, 2009; (Issue 1324)
The FDA has approved use of tadalafil (Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension...
The FDA has approved use of tadalafil (Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • October 22, 2007; (Issue 1272)
Ambrisentan (Letairis - Gilead), a selective endothelin type A (ETA) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial...
Ambrisentan (Letairis - Gilead), a selective endothelin type A (ETA) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial hypertension (PAH).
BiDil for Heart Failure
The Medical Letter on Drugs and Therapeutics • September 28, 2005; (Issue 1218)
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral...
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral vasodilators that have been used together off-label for many years to treat heart failure in patients not responding to other drugs.
Sildenafil (Revatio) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • August 15, 2005; (Issue 1215)
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now...
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.